Heart safety check for experimental liver drug
NCT ID NCT07263152
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This early-stage trial tested whether a single dose of hydronidone, an experimental drug for liver fibrosis, changes the heart's electrical activity (QTc interval) in 48 healthy Chinese adults. Participants received one of three doses or a placebo, and researchers measured how the drug affected their heart rhythm over time. The goal was to check safety, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Hydronidone capsules
- What this could lead to
- If successful, this study could help determine a safe dose range for hydronidone in future trials for liver fibrosis.
- What could go wrong
- This is an early-phase safety study in healthy people, not patients. It only looks at heart rhythm effects, not whether the drug works for liver disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Gobroad Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging tracer could spot hidden cancers and fibrosis in one scan
- Can a blood pressure drug reverse liver damage in hepatitis c?
- Simple blood test could spot silent liver damage early
- New liver drug safety trial begins for hepatitis b scarring
- Diet or drugs? new study tests if fasting beats pills for fatty liver disease
- Hidden pain in liver patients: a new study investigates